

Epizyme, Inc.
Form 8-K
January 17, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

January 17, 2019

EPIZYME, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of
Incorporation)

001-35945
(Commission File Number)

26-1349956
(IRS Employer Identification No.)

400 Technology Square,

02139

Cambridge, Massachusetts
(Address of Principal Executive Offices) **(Zip Code)**
Registrant's telephone number, including area code: (617) 229-5872
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Epizyme, Inc. (the "Company") announced that, effective January 31, 2019, Suzanne Fleming, the Company's Senior Vice President of Finance and Treasurer, will be leaving the Company to pursue other business opportunities. Matt Ros, the Company's Chief Strategy & Business Officer, will serve as the Company's principal financial officer effective on Ms. Fleming's departure.

Joseph Beaulieu, the Company's Controller, will assume the role of principal accounting officer of the Company effective on Ms. Fleming's departure. Mr. Beaulieu, 38, has served as the Company's Controller since July 2018. Prior to joining the Company, from July 2010 to July 2018, Mr. Beaulieu served as Manager and most recently Senior Manager at Ernst & Young LLP. Mr. Beaulieu received a Bachelor of Science degree with dual concentrations in accounting and management information systems from Boston College's Wallace E. Carrol School of Management.

Also in connection with Mr. Beaulieu's assumption of the role of principal accounting officer of the Company, Mr. Beaulieu will enter into the Company's standard form of indemnification agreement, a copy of which was filed as Exhibit 10.16 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (File No. 333-187982) filed with the SEC on April 26, 2013 and is incorporated herein by reference. Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify Mr. Beaulieu for some expenses, including attorneys fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as principal accounting officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIZYME, INC.

Date: January 17, 2019

By: /s/ Robert B. Bazemore
Robert B. Bazemore

President and Chief Executive Officer